<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: <z:chebi fb="1" ids="23019">Carbonyl</z:chebi> reductases (CBRs) catalyze reduction of <z:chebi fb="0" ids="48120">anthracyclines</z:chebi> to cardiotoxic alcohol metabolites </plain></SENT>
<SENT sid="1" pm="."><plain>Polymorphisms in CBR1 and CBR3 influence synthesis of these metabolites </plain></SENT>
<SENT sid="2" pm="."><plain>We examined whether single nucleotide polymorphisms in CBR1 (CBR1 1096G&gt;A) and/or CBR3 (CBR3 V244M) modified the dose-dependent risk of <z:chebi fb="0" ids="48120">anthracycline</z:chebi>-related <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> in <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">childhood cancer</z:e> survivors </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: One hundred seventy survivors with <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> (patient cases) were compared with 317 survivors with no <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> (controls; matched on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis, year of diagnosis, length of follow-up, and race/ethnicity) using conditional logistic regression techniques </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A dose-dependent association was observed between cumulative <z:chebi fb="0" ids="48120">anthracycline</z:chebi> exposure and <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> risk (0 mg/m(2): reference; 1 to 100 mg/m(2): odds ratio [OR], 1.65; 101 to 150 mg/m(2): OR, 3.85; 151 to 200 mg/m(2): OR, 3.69; 201 to 250 mg/m(2): OR, 7.23; 251 to 300 mg/m(2): OR, 23.47; &gt; 300 mg/m(2): OR, 27.59; P(trend) &lt; .001) </plain></SENT>
<SENT sid="5" pm="."><plain>Among individuals carrying the variant A allele (CBR1:GA/AA and/or CBR3:GA/AA), exposure to low- to moderate-dose <z:chebi fb="0" ids="48120">anthracyclines</z:chebi> (1 to 250 mg/m(2)) did not increase the risk of <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Among individuals with CBR3 V244M homozygous G genotypes (CBR3:GG), exposure to low- to moderate-dose <z:chebi fb="0" ids="48120">anthracyclines</z:chebi> increased <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> risk when compared with individuals with CBR3:GA/AA genotypes unexposed to <z:chebi fb="0" ids="48120">anthracyclines</z:chebi> (OR, 5.48; P = .003), as well as exposed to low- to moderate-dose <z:chebi fb="0" ids="48120">anthracyclines</z:chebi> (OR, 3.30; P = .006) </plain></SENT>
<SENT sid="7" pm="."><plain>High-dose <z:chebi fb="0" ids="48120">anthracyclines</z:chebi> (&gt; 250 mg/m(2)) were associated with increased <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> risk, irrespective of CBR genotype status </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: This study demonstrates increased <z:chebi fb="0" ids="48120">anthracycline</z:chebi>-related <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> risk at doses as low as 101 to 150 mg/m(2) </plain></SENT>
<SENT sid="9" pm="."><plain>Homozygosis for G allele in CBR3 contributes to increased <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> risk associated with low- to moderate-dose <z:chebi fb="0" ids="48120">anthracyclines</z:chebi>, such that there seems to be no safe dose for patients homozygous for the CBR3 V244M G allele </plain></SENT>
<SENT sid="10" pm="."><plain>These results suggest a need for targeted intervention for those at increased risk of <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
</text></document>